Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 601.45 | 555.51 | 600.18 | 548.12 | 341.46 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 601.45 | 555.51 | 600.18 | 548.12 | 341.46 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 11.58 | 10.32 | 8.31 | 43.07 | 5.31 |
Total Income | 613.03 | 565.83 | 608.49 | 591.2 | 346.77 |
Total Expenditure | 541.85 | 495.49 | 538.07 | 494.35 | 309.49 |
PBIDT | 71.18 | 70.34 | 70.42 | 96.85 | 37.29 |
Interest | 0.09 | 0.12 | 0.48 | 13.02 | 13.31 |
PBDT | 71.09 | 70.22 | 69.94 | 83.83 | 23.98 |
Depreciation | 26.44 | 32.3 | 33.53 | 35.28 | 32.01 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 12.22 | 0 | 0 | -13.21 | 1.96 |
Deferred Tax | 3.94 | 11.36 | -4.32 | 0 | 0 |
Reported Profit After Tax | 28.49 | 26.56 | 40.73 | 61.77 | -10 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 28.49 | 26.56 | 40.73 | 61.77 | -10 |
Extra-ordinary Items | 0 | 0 | 0 | 23.44 | -6.85 |
Adjusted Profit After Extra-ordinary item | 28.49 | 26.56 | 40.73 | 38.33 | -3.15 |
EPS (Unit Curr.) | 21.31 | 19.88 | 30.86 | 50.04 | -8.1 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 13.37 | 13.37 | 13.37 | 12.34 | 12.34 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 11.83 | 12.66 | 11.73 | 17.66 | 10.92 |
PBDTM(%) | 11.81 | 12.64 | 11.65 | 15.29 | 7.02 |
PATM(%) | 4.73 | 4.78 | 6.78 | 11.26 | -2.92 |
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice